Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Sep 26, 2017
Trial Information
Current as of May 03, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (1) acute leukemia in first complete or second complete remission;
- • (2) relapse after an allotransplant;
- • (3) had full or partial donor chimerism;
- • (4) received re-induction chemotherapy and DLI and achieved a negative MRD-test.
- Exclusion Criteria:
- • (1) active GvHD
- • (2) active infection
- • (3) organ dysfunction
About Peking University People's Hospital
Peking University People's Hospital is a leading clinical research institution in China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. Affiliated with Peking University, the hospital integrates cutting-edge research, comprehensive healthcare services, and a multidisciplinary team of experts to facilitate the development of new therapies and medical interventions. With a strong focus on patient safety and ethical standards, Peking University People's Hospital is dedicated to conducting rigorous clinical trials that contribute to the global medical community and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Xiao-jun Huang
Study Director
Peking University People's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials